瑞芬太尼与神经肌肉阻滞剂在误吸风险患者快速序贯插管中对无重大并发症成功插管的影响:一项随机临床试验
这项多中心、随机、开放标签、非劣效试验纳入1150例误吸风险成人(禁食<6小时、肠梗阻、近期创伤或严重胃食管反流),在法国15家医院手术室行气管插管,随机接受神经肌肉阻滞剂(琥珀胆碱或罗库溴铵1 mg/kg,n=575)或瑞芬太尼(3至4 μg/kg,n=575)。主要终点为首次插管成功且无重大并发症,瑞芬太尼组66.1% vs 神经肌肉阻滞剂组71.6%(校正差值-6.1%,95%CI -11.6%至-0.5%,非劣效P=.37),未达预设7.0%非劣效界值。瑞芬太尼组血流动力学不稳定不良事件3.3% vs 0.5%(校正差值2.8%,95%CI 1.2%-4.4%)。作者认为虽统计学劣于神经肌肉阻滞剂,但宽置信区间仍与优效相容,限制了对差异临床相关性的结论。
要点
- 误吸风险成人快速序贯插管,瑞芬太尼组无重大并发症首次插管成功66.1%(374/575) vs 神经肌肉阻滞剂组71.6%(408/575),校正差值-6.1%(95%CI -11.6%至-0.5%),非劣效P=.37,未达7.0%非劣效界值。
- 符合方案人群中瑞芬太尼组66.2%(374/565) vs 神经肌肉阻滞剂组71.3%(403/565),校正差值-5.7%(95%CI -11.3%至-0.1%),非劣效P=.32。
- 瑞芬太尼组血流动力学不稳定不良事件3.3%(19/575) vs 神经肌肉阻滞剂组0.5%(3/575),校正差值2.8%(95%CI 1.2%-4.4%)。
- 作者认为瑞芬太尼虽统计学劣于神经肌肉阻滞剂,但效应估计的宽置信区间仍与优效相容,限制了对差异临床相关性的结论。
适用人群与场景
- 纳入存在误吸风险的成人(禁食<6小时、肠梗阻、近期创伤或严重胃食管反流),在法国15家医院手术室行气管插管,2019年10月至2021年4月入组,随访至2021年5月15日完成。
诊断标准与关键阈值
- 主要终点为首次气管插管成功且无重大并发症,重大并发症定义为消化道内容物肺误吸、氧饱和度下降、重大血流动力学不稳定、持续性心律失常、心脏骤停和严重过敏反应。
- 预设非劣效界值为7.0%。
处置流程与药物剂量
- 在注射催眠药后立即给予神经肌肉阻滞剂(琥珀胆碱或罗库溴铵1 mg/kg,n=575)或瑞芬太尼(3至4 μg/kg,n=575)。
研究设计与关键结果
- 多中心、随机、开放标签、非劣效试验,1150例误吸风险成人随机,1130例(98.3%)完成试验;平均年龄50.7岁(SD 17.4),573例(50%)女性。
- 按随机分组人群:瑞芬太尼组首次插管成功且无重大并发症374/575(66.1%) vs 神经肌肉阻滞剂组408/575(71.6%),校正随机分层和中心的组间差值-6.1%(95%CI -11.6%至-0.5%),非劣效P=.37,显示劣效。
- 符合方案人群:瑞芬太尼组374/565(66.2%) vs 神经肌肉阻滞剂组403/565(71.3%),校正差值-5.7%(双侧95%CI -11.3%至-0.1%),非劣效P=.32。
- 血流动力学不稳定不良事件:瑞芬太尼组19/575(3.3%) vs 神经肌肉阻滞剂组3/575(0.5%),校正差值2.8%(95%CI 1.2%-4.4%)。
证据类型、等级与局限
- 证据类型:多中心、随机、开放标签、非劣效试验;原文未报告证据等级。
- 局限:作者指出瑞芬太尼虽统计学劣于神经肌肉阻滞剂,但效应估计的宽置信区间仍与优效相容,限制了对差异临床相关性的结论。
对床旁实践的改变
- 作者认为,在手术室误吸风险成人快速序贯插管中,瑞芬太尼相比神经肌肉阻滞剂未达到无重大并发症首次插管成功的非劣效标准;虽统计学劣于神经肌肉阻滞剂,但宽置信区间仍与优效相容,限制了对差异临床相关性的结论。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: It is uncertain whether a rapid-onset opioid is noninferior to a rapid-onset neuromuscular blocker during rapid sequence intubation when used in conjunction with a hypnotic agent.
OBJECTIVE: To determine whether remifentanil is noninferior to rapid-onset neuromuscular blockers for rapid sequence intubation.
DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, open-label, noninferiority trial among 1150 adults at risk of aspiration (fasting for <6 hours, bowel occlusion, recent trauma, or severe gastroesophageal reflux) who underwent tracheal intubation in the operating room at 15 hospitals in France from October 2019 to April 2021. Follow-up was completed on May 15, 2021.
INTERVENTIONS: Patients were randomized to receive neuromuscular blockers (1 mg/kg of succinylcholine or rocuronium; n = 575) or remifentanil (3 to 4 μg/kg; n = 575) immediately after injection of a hypnotic.
MAIN OUTCOMES AND MEASURES: The primary outcome was assessed in all randomized patients (as-randomized population) and in all eligible patients who received assigned treatment (per-protocol population). The primary outcome was successful tracheal intubation on the first attempt without major complications, defined as lung aspiration of digestive content, oxygen desaturation, major hemodynamic instability, sustained arrhythmia, cardiac arrest, and severe anaphylactic reaction. The prespecified noninferiority margin was 7.0%.
RESULTS: Among 1150 randomized patients (mean age, 50.7 [SD, 17.4] years; 573 [50%] women), 1130 (98.3%) completed the trial. In the as-randomized population, tracheal intubation on the first attempt without major complications occurred in 374 of 575 patients (66.1%) in the remifentanil group and 408 of 575 (71.6%) in the neuromuscular blocker group (between-group difference adjusted for randomization strata and center, -6.1%; 95% CI, -11.6% to -0.5%; P = .37 for noninferiority), demonstrating inferiority. In the per-protocol population, 374 of 565 patients (66.2%) in the remifentanil group and 403 of 565 (71.3%) in the neuromuscular blocker group had successful intubation without major complications (adjusted difference, -5.7%; 2-sided 95% CI, -11.3% to -0.1%; P = .32 for noninferiority). An adverse event of hemodynamic instability was recorded in 19 of 575 patients (3.3%) with remifentanil and 3 of 575 (0.5%) with neuromuscular blockers (adjusted difference, 2.8%; 95% CI, 1.2%-4.4%).
CONCLUSIONS AND RELEVANCE: Among adults at risk of aspiration during rapid sequence intubation in the operating room, remifentanil, compared with neuromuscular blockers, did not meet the criterion for noninferiority with regard to successful intubation on first attempt without major complications. Although remifentanil was statistically inferior to neuromuscular blockers, the wide confidence interval around the effect estimate remains compatible with noninferiority and limits conclusions about the clinical relevance of the difference.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03960801.
参考来源
- Grillot N, Lebuffe G, Huet O, et al. Effect of Remifentanil vs Neuromuscular Blockers During Rapid Sequence Intubation on Successful Intubation Without Major Complications Among Patients at Risk of Aspiration: A Randomized Clinical Trial. JAMA. 2023. PMID: 36594947. doi:10.1001/jama.2022.23550
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。